Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors

Thoracic Cancer
Zhigang WeiJie Wang

Abstract

Multiple prospective studies have demonstrated that epidermal growth factor receptor (EGFR) exon 19 and exon 21 mutations are the most powerful predictive biomarkers of response to EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small-cell lung cancer (NSCLC). However, there are few studies focused on patients with double mutations compared with a single mutation. We retrospectively screened 1,525 samples of Chinese patients with advanced NSCLC who underwent EGFR mutation detections in tumor tissues at Peking University Cancer Hospital between February 2006 and March 2011. Thirty-two cases harboring double mutations were included in this study. The Kaplan-Meier univariate analysis for prognostic factors of survival was applied. Patients with double mutations accounted for 2.1% (32/1525) of the overall tested samples. Double mutations were more common in female, adenocarcinoma, non-smokers, Eastern Cooperative Oncology Group (ECOG0)-1 and stage IV patients. Twenty-one patients with double mutations were treated with EGFR-TKIs. The objective response rate (ORR) was 23.8%, and the disease control rate (DCR) was 76.2%. In the first-line therapy, the ORR was 16.7%, and the DCR was 66.7%. In univariate analysis, gender, smokin...Continue Reading

References

Mar 22, 2003·Experimental Cell Research·Carlos L Arteaga
Jul 18, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fred R HirschWilbur A Franklin
Mar 3, 2005·Journal of the National Cancer Institute·Hisayuki ShigematsuAdi F Gazdar
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory J RielyVincent A Miller
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emiliano Calvo, José Baselga
Nov 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fred R HirschBrian Holloway
Jun 1, 2007·Clinical Oncology : a Journal of the Royal College of Radiologists·G-C ZhangY-L Wu
Apr 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amit KumarTitus J Boggon
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chang-Qi ZhuUNKNOWN National Cancer Institute of Canada Clinical Trials Group Study BR.21
Aug 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jenn-Yu WuPan-Chyr Yang
May 6, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hua BaiJie Wang
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Aug 21, 2009·The New England Journal of Medicine·Rafael RosellUNKNOWN Spanish Lung Cancer Group
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group

❮ Previous
Next ❯

Citations

Dec 29, 2015·Asia-Pacific Journal of Clinical Oncology·Hoang Anh VuNguyen Sao Trung
Dec 10, 2016·Scientific Reports·Kikuya KatoFumio Imamura
Dec 23, 2017·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Hua-Li LiuQi-Bin Song
Jun 28, 2018·The International Journal of Biological Markers·Francesca BelardinilliGiuseppe Giannini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.